TOKYO -- Trans Genic, a gene analysis company that carries out preclinical trials for pharmaceutical companies, has downgraded its fiscal 2019 earnings due to the coronavirust epidemic in China.
The company has been unable to import lab monkeys from China it uses for contract trials due to customs restrictions following the outbreak.
